Anti‐IL13 or anti‐IL4 agents vs placebo
Adverse events (any) · people with asthma
Anti‐IL13 or anti‐IL4 agents leads to higher adverse events (any) compared with placebo (high certainty).
1 finding from 1 review
- Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes onlyOR 1.16 [1.04, 1.3]18 studies · 7419 participantsHigh